Daily Stock Analysis, BNTC, Benitec Biopharma Ltd, priceseries

Benitec Biopharma Ltd. Daily Stock Analysis
Stock Information
Open
2.68
Close
2.75
High
2.79
Low
2.68
Previous Close
2.61
Daily Price Gain
0.14
YTD High
5.48
YTD High Date
Apr 4, 2017
YTD Low
0.00
YTD Low Date
Nov 14, 2017
YTD Price Change
1.19
YTD Gain
76.28%
52 Week High
5.48
52 Week High Date
Apr 4, 2017
52 Week Low
0.00
52 Week Low Date
Nov 14, 2017
52 Week Price Change
1.20
52 Week Gain
77.42%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jul 19. 2016
1.69
Jul 20. 2016
1.85
1 Trading Days
9.16%
Link
LONG
Jan 19. 2017
2.15
Jan 20. 2017
2.26
1 Trading Days
5.19%
Link
LONG
Feb 6. 2017
2.49
Feb 13. 2017
2.66
5 Trading Days
6.93%
Link
LONG
Oct 2. 2017
2.17
Oct 6. 2017
2.45
4 Trading Days
12.70%
Link
LONG
Oct 11. 2017
2.46
Oct 13. 2017
2.66
2 Trading Days
7.93%
Link
LONG
Oct 17. 2017
2.77
Oct 18. 2017
2.97
1 Trading Days
7.22%
Link
Company Information
Stock Symbol
BNTC
Exchange
NasdaqCM
Company URL
http://www.benitec.com
Company Phone
-
CEO
Gregory C. West
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
-
About

company, which develops innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. The company has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa. Its clinical pipeline is focused on market opportunities in Hepatitis C, Hepatitis B, lung cancer and wet Age-related Macular Degeneration, as well as the orphan genetic disease, oculopharyngeal muscular dystrophy. Benitec Biopharma was founded by Kenneth C. Reed in 1997 and is headquartered in Melbourne, Australia.

Description

Developing gene therapies for hepatitis C based on RNA interference.